• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.慢性丙型肝炎患者中与干扰素α-2b和利巴韦林联合治疗相关的视网膜病变的危险因素。
World J Gastroenterol. 2006 Jun 21;12(23):3756-9. doi: 10.3748/wjg.v12.i23.3756.
2
Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.埃及慢性丙型肝炎病毒患者接受聚乙二醇干扰素加利巴韦林治疗后发生视网膜病变的发生率和危险因素。
Int J Infect Dis. 2012 Jan;16(1):e67-71. doi: 10.1016/j.ijid.2011.09.022. Epub 2011 Nov 23.
3
[Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].[慢性丙型肝炎患者在干扰素联合利巴韦林治疗期间的视网膜病变]
Nippon Ganka Gakkai Zasshi. 2005 Nov;109(11):748-52.
4
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.慢性丙型肝炎患者在接受干扰素联合利巴韦林治疗期间的视网膜病变。
Br J Ophthalmol. 2001 Oct;85(10):1171-3. doi: 10.1136/bjo.85.10.1171.
5
Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?慢性丙型肝炎感染患者的干扰素和利巴韦林联合治疗对眼睛有毒性吗？
J Ocul Pharmacol Ther. 2013 Apr;29(3):345-8. doi: 10.1089/jop.2012.0169. Epub 2012 Oct 31.
6
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.聚乙二醇干扰素联合利巴韦林治疗丙型肝炎患者的视网膜病变。
Jpn J Ophthalmol. 2009 Nov;53(6):598-602. doi: 10.1007/s10384-009-0738-8. Epub 2009 Dec 18.
7
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.接受干扰素和利巴韦林治疗的丙型肝炎患者的后段并发症
Ophthalmology. 2003 Feb;110(2):437-42. doi: 10.1016/S0161-6420(02)01741-4.
8
Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.丙型肝炎：治疗的诊断、管理及眼部并发症综述
Optometry. 2003 Aug;74(8):517-23.
9
[Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].丙型肝炎患者聚乙二醇干扰素和利巴韦林相关视网膜病变
Arch Soc Esp Oftalmol. 2011 Jun;86(6):193-5. doi: 10.1016/j.oftal.2010.12.015. Epub 2011 Apr 29.
10
Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.慢性丙型肝炎干扰素α治疗期间的视网膜并发症与血浆C5a水平
Am J Gastroenterol. 1998 Dec;93(12):2441-4. doi: 10.1111/j.1572-0241.1998.00701.x.

引用本文的文献

1
A Drop in Hemoglobin as an Association with Pegylated Interferon Retinopathy: A Novel Pathophysiology.血红蛋白下降与聚乙二醇化干扰素视网膜病变的关联：一种新的病理生理学。
J Curr Ophthalmol. 2020 Apr 30;32(2):195-198. doi: 10.4103/JOCO.JOCO_103_20. eCollection 2020 Apr-Jun.
2
Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.慢性丙型肝炎治疗中干扰素-α 诱导的视网膜病变：总结、考量与建议
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):447-452. doi: 10.1007/s00417-018-04209-7. Epub 2018 Dec 13.
3
Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study.接受抗丙型肝炎病毒治疗的丙型肝炎患者患白内障风险增加：一项全国性队列研究。
PLoS One. 2017 Mar 6;12(3):e0173125. doi: 10.1371/journal.pone.0173125. eCollection 2017.
4
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.加拿大卫生研究院加拿大HIV试验网络合并感染与并发疾病核心研究小组：2016年更新的加拿大成人HIV/丙型肝炎管理与治疗指南
Can J Infect Dis Med Microbiol. 2016;2016:4385643. doi: 10.1155/2016/4385643. Epub 2016 Jul 4.
5
Ophthalmological side effects of interferon therapy of chronic hepatitis C.慢性丙型肝炎干扰素治疗的眼科副作用
Hepatobiliary Surg Nutr. 2016 Jun;5(3):209-16. doi: 10.21037/hbsn.2015.12.14.
6
KASL clinical practice guidelines: management of hepatitis C.KASL临床实践指南：丙型肝炎的管理
Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28.
7
Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy.接受聚乙二醇化干扰素α-2a与利巴韦林联合治疗的慢性丙型肝炎患者视网膜病变的发生率
Pak J Med Sci. 2015 Jan-Feb;31(1):174-7. doi: 10.12669/pjms.311.6321.
8
KASL clinical practice guidelines: management of hepatitis C.KASL临床实践指南：丙型肝炎的管理
Clin Mol Hepatol. 2014 Jun;20(2):89-136. doi: 10.3350/cmh.2014.20.2.89. Epub 2014 Jun 30.
9
Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.糖尿病合并高血压丙型肝炎患者的干扰素相关视网膜病变风险
World J Gastroenterol. 2014 Jun 21;20(23):7505-13. doi: 10.3748/wjg.v20.i23.7505.
10
Transient visual loss in a hepatitis C patient treated with pegylated interferon alfa-2a and ribavirin.一名接受聚乙二醇化干扰素α-2a和利巴韦林治疗的丙型肝炎患者出现短暂性视力丧失。
Hepat Mon. 2014 Feb 20;14(2):e15124. doi: 10.5812/hepatmon.15124. eCollection 2014 Feb.

本文引用的文献

1
Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.聚乙二醇化α-干扰素治疗慢性丙型肝炎期间的视网膜毒性：一项多焦视网膜电图研究
Aliment Pharmacol Ther. 2005 Mar 15;21(6):723-32. doi: 10.1111/j.1365-2036.2005.02365.x.
2
Is screening for interferon retinopathy in hepatitis C justified?丙型肝炎中干扰素视网膜病变的筛查是否合理？
Br J Ophthalmol. 2004 Dec;88(12):1518-20. doi: 10.1136/bjo.2004.043968.
3
Diagnosis, management, and treatment of hepatitis C.丙型肝炎的诊断、管理与治疗。
Hepatology. 2004 Apr;39(4):1147-71. doi: 10.1002/hep.20119.
4
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.接受干扰素和利巴韦林治疗的丙型肝炎患者的后段并发症
Ophthalmology. 2003 Feb;110(2):437-42. doi: 10.1016/S0161-6420(02)01741-4.
5
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.慢性丙型肝炎患者在接受干扰素联合利巴韦林治疗期间的视网膜病变。
Br J Ophthalmol. 2001 Oct;85(10):1171-3. doi: 10.1136/bjo.85.10.1171.
6
Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.慢性丙型肝炎自然干扰素-α统一治疗方案中的干扰素相关性视网膜病变
Liver. 2001 Jun;21(3):192-7. doi: 10.1034/j.1600-0676.2001.021003192.x.
7
Retinopathy associated with high-dose interferon alfa-2b therapy.与高剂量干扰素α-2b治疗相关的视网膜病变
Am J Ophthalmol. 2001 Jun;131(6):782-7. doi: 10.1016/s0002-9394(01)00836-4.
8
Hepatitis C--global prevalence (update).丙型肝炎——全球患病率（更新）
Wkly Epidemiol Rec. 1999 Dec 10;74(49):425-7.
9
Ocular complications with high-dose interferon alpha in chronic active hepatitis.高剂量干扰素α治疗慢性活动性肝炎的眼部并发症
Eye (Lond). 1999 Apr;13 ( Pt 2):241-6. doi: 10.1038/eye.1999.59.
10
Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study.视网膜小动脉直径与血压升高：社区动脉粥样硬化风险研究
Am J Epidemiol. 1999 Aug 1;150(3):263-70. doi: 10.1093/oxfordjournals.aje.a009997.

慢性丙型肝炎患者中与干扰素α-2b和利巴韦林联合治疗相关的视网膜病变的危险因素。

Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.

作者信息

Okuse Chiaki, Yotsuyanagi Hiroshi, Nagase Yoshihiko, Kobayashi Yuhtaro, Yasuda Kiyomi, Koike Kazuhiko, Iino Shiro, Suzuki Michihiro, Itoh Fumio

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.

出版信息

World J Gastroenterol. 2006 Jun 21;12(23):3756-9. doi: 10.3748/wjg.v12.i23.3756.

DOI:10.3748/wjg.v12.i23.3756
PMID:16773695
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4087471/
Abstract

AIM

To elucidate the frequency and risk factors for retinopathy in patients with chronic hepatitis C who are treated by interferon-ribavirin combination therapy.

METHODS

We prospectively analyzed 73 patients with histologically confirmed chronic hepatitis C, who underwent combination therapy for 24 wk. Optic fundi were examined before, and 2, 4, 12 and 24 wk after the start of combination therapy.

RESULTS

Fourteen patients (19%) developed retinopathy, which was initially diagnosed by the appearance of a cotton wool spot in 12 patients. Retinal hemorrhage was observed in 5 patients. No patient complained of visual disturbance. Retinopathy disappeared in 9 patients (64%) despite the continuation of combination therapy. However, retinopathy persisted in 5 patients with retinal hemorrhage. A comparison of the clinical background between the groups with and without retinopathy showed no significant differences in age, gender, viral genotype, RNA level, white blood cell count, platelet count, prothrombin time, complications by diabetes mellitus or hypertension, or pretreatment arteriosclerotic changes in the optic fundi. However, multiple logistic regression analysis revealed that complication by hypertension was observed with a high frequency in the group with retinopathy (P = 0.004, OR = 245.918, 95% CI = 5.6-10786.2).

CONCLUSION

Retinopathy associated with combination therapy of interferon alpha-2b and ribavirin tends to develop in patients with hypertension.

摘要

目的

阐明接受干扰素 - 利巴韦林联合治疗的慢性丙型肝炎患者视网膜病变的发生率及危险因素。

方法

我们前瞻性分析了73例经组织学确诊的慢性丙型肝炎患者，他们接受了为期24周的联合治疗。在联合治疗开始前以及开始后2周、4周、12周和24周对眼底进行检查。

结果

14例患者（19%）发生视网膜病变，其中12例最初通过棉絮斑的出现得以诊断。5例患者观察到视网膜出血。无患者主诉视力障碍。尽管继续联合治疗，但9例患者（64%）的视网膜病变消失。然而，5例有视网膜出血的患者视网膜病变持续存在。有视网膜病变组和无视网膜病变组临床背景的比较显示，在年龄、性别、病毒基因型、RNA水平、白细胞计数、血小板计数、凝血酶原时间、糖尿病或高血压并发症或治疗前眼底动脉硬化改变方面无显著差异。然而，多因素logistic回归分析显示，视网膜病变组高血压并发症的发生率较高（P = 0.004，OR = 245.918，95%CI = 5.6 - 10786.2）。

结论

与干扰素α - 2b和利巴韦林联合治疗相关的视网膜病变倾向于在高血压患者中发生。